Preoperative markers for the prediction of high-risk features in endometrial cancer.

BACKGROUND Preoperative evaluations aiming to assess high-risk features in clinical stage 1 endometrial cancer patients are crucial to refer these patients to gynecologic oncologists. Cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) have been reported in endometrial cancer patients with poor prognostic factors. AIM To evaluate the association between preoperative levels of CA125 and HE4 and high-risk features and establish optimal cut-off values in clinical stage 1 endometrial cancer. METHODS A retrospective study was conducted in clinical stage 1 endometrial cancer patients who underwent primary surgery between January 2013 and December 2018. A total of 128 patients had preoperative serum CA125 and HE4 measurements. High-risk features included grade 3 tumors, large tumor sizes (more than 2 cm), deep myometrial invasion (more than 50%), lymphovascular space invasion (LVSI), cervical involvement, extrauterine involvement and node metastasis. Receiver operating characteristic (ROC) curves were generated to analyze the optimal cut-off values. RESULTS The mean age of the patients was 57.4 years, and 69.5% of them were postmenopausal. Most patients presented with stage I disease (67.2%) and had the endometrioid subtype (97.7%). The median CA125 and HE4 levels in all patients were 22.1 U/mL and 104.7 pmol/L, respectively. CA125 and HE4 levels were significantly elevated in those with large tumor sizes, deep myometrial invasion, LVSI, extrauterine metastasis, and advanced stage, but node metastasis was associated with elevated CA125 only. According to the ROC curve, both serum markers had statistical significance for the prediction of high-risk features only in postmenopausal patients, with an optimal cut-off value of 20 U/mL for CA125 [area under the concentration-time curve (AUC) = 0.72, P = 0.002] and 113 pmol/L for HE4 (AUC = 0.70, P = 0.006). The combination of both serum markers had 80% sensitivity and 64.4% positive predictive value. Significantly worse 5-year disease-free survival was observed in patients with high levels of CA125 and HE4 (78.4% and 100%, respectively; P = 0.01). CONCLUSION Preoperative CA125 levels greater than 20 U/mL or HE4 levels greater than 113 pmol/L are associated with an increased risk of having high-risk features and present as prognostic factors in clinical stage 1 postmenopausal endometrial cancer patients. This information is helpful for general gynecologists to refer high-risk patients to gynecologic oncologists to perform complete surgical staging.

[1]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[2]  F. Amant,et al.  Cancer of the corpus uteri , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[3]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[4]  Kathleen R. Cho,et al.  Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  A. Blejec,et al.  Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. , 2017, Gynecologic oncology.

[6]  Ping Liu,et al.  Value of HE4 Combined with Cancer Antigen 125 in the Diagnosis of Endometrial Cancer , 2017, Pakistan journal of medical sciences.

[7]  K. van de Vijver,et al.  Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer , 2017, Virchows Archiv.

[8]  R. Kučera,et al.  Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management. , 2017, Anticancer research.

[9]  Yingmei Wang,et al.  Predictive value of serum HE4 and CA125 concentrations for lymphatic metastasis of endometrial cancer , 2017, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  M. Yanaranop,et al.  Association of Serum HE4 with Primary Tumor Diameter and Depth of Myometrial Invasion in Endometrial Cancer Patients at Rajavithi Hospital. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[11]  A. Weaver,et al.  Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer. , 2014, Gynecologic oncology.

[12]  Alexander M. Metcalf,et al.  Serum HE4 as a prognostic marker in endometrial cancer--a population based study. , 2014, Gynecologic oncology.

[13]  I. Christensen,et al.  HE4 and CA125 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET) , 2013, Acta obstetricia et gynecologica Scandinavica.

[14]  R. Angioli,et al.  The role of novel biomarker HE4 in endometrial cancer: a case control prospective study , 2013, Tumor Biology.

[15]  H. Fiegl,et al.  HE4 is an independent prognostic marker in endometrial cancer patients. , 2012, Gynecologic oncology.

[16]  K. Nustad,et al.  Human epididymis protein 4 reference limits and natural variation in a Nordic reference population , 2011, Tumor Biology.

[17]  Shih-hung Huang,et al.  Value of pre‐operative serum CA125 level for prediction of prognosis in patients with endometrial cancer , 2011, The Australian & New Zealand journal of obstetrics & gynaecology.

[18]  E. Morii,et al.  Intraoperative Frozen Section Assessment of Myometrial Invasion and Histology of Endometrial Cancer Using the Revised FIGO Staging System , 2011, International Journal of Gynecologic Cancer.

[19]  J. W. Kim,et al.  Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study. , 2010, Gynecologic oncology.

[20]  S. Kehoe,et al.  Serum tumour markers in gynaecological cancers. , 2010, Maturitas.

[21]  N. Park,et al.  Evaluation of preoperative criteria used to predict lymph node metastasis in endometrial cancer , 2010, Acta obstetricia et gynecologica Scandinavica.

[22]  T. Manchana,et al.  Is Complete Surgical Staging Necessary in Clinically Early-Stage Endometrial Carcinoma? , 2009, International Journal of Gynecologic Cancer.

[23]  Richard G. Moore,et al.  Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. , 2008, Gynecologic oncology.

[24]  J. Berek,et al.  Prognostic Factors for Uterine Cancer in Reproductive-Aged Women , 2007, Obstetrics and gynecology.

[25]  N. Park,et al.  Use of preoperative serum CA‐125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer , 2006, Acta obstetricia et gynecologica Scandinavica.

[26]  W. Gajewski,et al.  Preoperative serum CA-125 levels in treating endometrial cancer. , 2005, The Journal of reproductive medicine.

[27]  Patrick Neven,et al.  Endometrial cancer. , 2005, Lancet.

[28]  T. Nishimura,et al.  Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. , 1998, Gynecologic oncology.